aurotioprol and Arthritis

The paper is concerned with the results of a 6- and 12-month comparative randomized study of the efficacy of chrysanol (calcium-aurothiopropanol-sulfonate) in 21 patients with verified psoriatic arthritis. Patients of the study group (11 patients) received in addition to chrysanol nonsteroid antiinflammatory drugs (NAD), patients of the control group (10) received NAD only. The efficacy of annual treatment was assessed in 10 patients (5 in each group). Therapeutic efficacy was assessed on the basis of an analysis of 19 clinical and laboratory findings. Six months later improvement was noted in 80% of the patients of the study group, of them considerable improvement in 30%. A significant positive time course was observed for 9 parameters including those characterizing vertebral mobility. Improvement in the control group was noted in 50% of the patients, 2 parameters changed significantly. One year later improvement was recorded in all the patients of the study group and in 40% of the patients of the control group. A significant positive time course was noted for 10 parameters in the study group and not a single one in the control group. In the latter group 7 values got worse, the deterioration of one value was statistically significant. Side effects of chrysanol were noted in 2 patients (agranulocytosis and nephropathy). The aggravation of skin psoriasis was not noted in any patients.

Topics: Adult; Arthritis; Clinical Trials as Topic; Dimercaprol; Drug Therapy, Combination; Female; Gold; Humans; Indomethacin; Male; Organogold Compounds; Organometallic Compounds; Propanols; Psoriasis; Random Allocation; Sulfhydryl Compounds

Oral gold (auranofin) has been used in 31 patients, 20 with active rheumatoid arthritis and 11 with active psoriatic arthritis. In rheumatoid arthritis the oral gold treatment was compared to parenteral gold treatment in a patient blind trial for two years. The psoriatic arthritis cases were incorporated in an open trial. Auranofin 6 mg once daily reduced significantly the activity in rheumatoid arthritis and in psoriatic arthritis. The beneficial effect obtained with auranofin at a dose of 6 mg/day during the first year of treatment could not be maintained by 3 mg/day in the second year. Auranofin compared to parenteral gold had a distinct advantage of better systemic tolerability, although parenteral gold was found to be more potent. There was no greater risk for toxic skin reaction to oral gold in psoriatic arthritis than in rheumatoid arthritis. The overall conclusion of this longterm study is that oral gold (auranofin) 6 mg once daily, although slightly less effective than parenteral gold, can be considered to be the first choice of gold treatment for rheumatoid arthritis and psoriatic arthritis, because the compliance, which is a reflection of a combination of tolerance and efficacy, for oral gold therapy was, in our hands, undoubtedly superior to parenteral gold.

Topics: Adult; Anti-Inflammatory Agents; Arthritis; Arthritis, Rheumatoid; Auranofin; Aurothioglucose; Clinical Trials as Topic; Dimercaprol; Double-Blind Method; Female; Gold; Humans; Long-Term Care; Male; Middle Aged; Organogold Compounds; Organometallic Compounds; Patient Compliance; Propanols; Prospective Studies; Psoriasis; Random Allocation; Sulfhydryl Compounds

The authors describe the association of gold salt-induced cholestasis and lymphocytic alveolitis proved by liver biopsy and broncho-alveolar lavage. To our knowledge this is the third case report on the combination of liver disease and pulmonary infiltration induced by gold compounds.

Topics: Aged; Arthritis; Cholestasis; Dimercaprol; Gold; Humans; Male; Metalloproteins; Organogold Compounds; Organometallic Compounds; Propanols; Pulmonary Fibrosis; Sulfhydryl Compounds

Topics: Anti-Inflammatory Agents; Arthritis; Chorea; Dimercaprol; Female; Gold; Humans; Middle Aged; Organogold Compounds; Organometallic Compounds; Propanols; Sulfhydryl Compounds

Topics: Arthritis; Arthritis, Rheumatoid; Drug Therapy; Eosinophilia; Gold; Humans; Organogold Compounds; Pneumonia; Propanols; Pulmonary Eosinophilia; Sulfhydryl Compounds; Toxicology